Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

PaperCitations, authors & open-access status

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial* is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 120 citations, 2020 year and hybrid oa status.

120
Citations
2020
Year
hybrid
OA Status

Related on ScholarIQ

Yayoi Tada
Author
British Journal of Dermatology
Journal
Psoriasis: Treatment and Pathogenesis
Topic
Psoriasis: Treatment and Pathogenesis
Topic
Autoimmune Bullous Skin Diseases
Topic
Cytokine Signaling Pathways and Interactions
Topic
470M+ articles · free account